The problem of chronic refractory angina. Report from the ESC Joint Study Group on the Treatment of Refractory Angina

Mannheimer, Clas

doi:10.1053/euhj.2001.2706

Cited by 428 publications

(329 citation statements)

References 126 publications

Supporting

Mentioning

306

Contrasting

Unclassified

Order By: Relevance

“…Treatment of CAD consists of medical, invasive surgical and non-surgical coronary interventions (3). Despite of those therapies, there are still many symptomatic patients who are not good candidates for coronary interventions (4,5). Several non-pharmacological options for the treatment of patients with angina pectoris, with or without underlying HF, have been suggested.…”

Section: Introductionmentioning

confidence: 99%

Clinical effects of enhanced external counterpulsation treatment in patients with ischemic heart failure

Kozdağ¹,

Ertaş²,

Aygün³

et al. 2012

Anadolu Kardiyol Derg

View full text Add to dashboard Cite

Objective: Enhanced external counterpulsation (EECP) is a noninvasive treatment that is proven safe and effective in patients with coronary artery disease (CAD) and heart failure (HF). The aims of this study are to investigate the clinical effects of EECP therapy in patients with symptomatic CAD and chronic HF, and to find out an answer to the question: Does EECP therapy have any effect on the prognostic markers of HF? Methods: This study was designed as a prospective cohort study. A total of 68 consecutive patients with symptomatic CAD and chronic HF referred to EECP therapy were enrolled in this study between November 2007 and December 2010; 47 patients (39 males and 8 females, 65±7, years), have undergone EECP treatment, and 21 patients (20 males and 1 female, 62±10 years), who did not want to participate in the EECP program comprised the control group. Statistical analysis was performed using t tests for dependent and independent samples, Mann-Whitney U test, Chi-square and Fischer exact tests. Results: EECP therapy resulted in significant improvement in post-intervention New York Heart Association functional class (p<0.001), left ventricular ejection fraction (p<0.001), B-type natriuretic peptide levels (p<0.003), uric acid levels (p<0.05), free-T3/free-T4 ratio (p<0.034) and mitral annular E (p<0.05) velocity, compared with baseline, a finding not evident in the control group. Conclusion: EECP treatment significantly improved clinical and some biochemical parameters, which are mostly prognostic markers in patients with symptomatic CAD and chronic HF. (Anadolu Kardiyol Derg 2012; 12: 214-21)

show abstract

Section: Introductionmentioning

confidence: 99%

Clinical effects of enhanced external counterpulsation treatment in patients with ischemic heart failure

Kozdağ¹,

Ertaş²,

Aygün³

et al. 2012

Anadolu Kardiyol Derg

View full text Add to dashboard Cite

show abstract

“…1 Enhanced external counterpulsation (EECP) is a potential treatment that is safe, noninvasive, and technically simple. It involves application of pneumatic cuffs to the lower extremities, which are sequentially inflated during diastole and simultaneously deflated prior to the onset of systole.…”

Section: Introductionmentioning

confidence: 99%

Enhanced External Counterpulsation in the Treatment of Chronic Refractory Angina: A Long‐term Follow‐up Outcome from the International Enhanced External Counterpulsation Patient Registry

Loh

Cleland

Louis

et al. 2008

Clinical Cardiology

View full text Add to dashboard Cite

BackgroundThe management of patients who suffer from medically refractory angina and are unsuitable for conventional revascularization therapy is often unsatisfactory. Enhanced external counterpulsation (EECP) is a noninvasive treatment that is safe and effective immediately after a course of treatment. However, the duration of benefit is less certain.HypothesisTo evaluate the 3‐year outcome of EECP treatment.MethodsOne thousand four hundred and twenty seven patients from 36 centers registered in the International EECP Patient Registry (IEPR)—Phase 1 was prospectively followed for a median of 37 months. Two hundred and twenty patients (15.4%) died, while 1,061 patients (74.4%) completed their follow‐up.ResultsThe mean age was 66 ± 11 years and 72% were men. Seventy‐six percent had multivessel coronary disease for 11 ± 8 years. Eighty‐eight percent had a prior percutaneous or surgical revascularization and 82% were unsuitable for further coronary intervention.Immediately post‐EECP, the proportion of patients with severe angina (Canadian Cardiovascular Angina Classification [CCS] III/IV) were reduced from 89% to 25%, p<0.001. The CCS class was improved by at least 1 class in 78% of the patients and by at least 2 classes in 38%. This was sustained in 74% of the patients during follow‐up.Thirty‐six percent of the patients had CCS II or less angina, which was better than pre‐EECP state without a major adverse cardiovascular event during follow‐up. More severe baseline angina and a history of heart failure or diabetes were independent predictors of unfavorable outcome.ConclusionAn EECP improves angina and quality of life immediately after a course of treatment. For most of the patients, these beneficial effects are sustained for 3 years. Copyright © 2008 Wiley Periodicals, Inc.

show abstract

“…Une étude chez des patients ayant subi une revascularisation percutanée a montré une prévalence combinée de l'angor et des événements coronaires de plus de 18 % [1] et la nécessité d'un traitement anti-angineux chez plus de 60 % des patients. Par ailleurs, une revascularisation myocardique n'est pas toujours indiquée, même en cas de symptomatologie sévère [2]. Si l'utilité du traitement médical conventionnel anti-ischémique (β-bloquants, inhibiteurs calciques, dérivés nitrés) n'est plus à démontrer, il connaît pourtant des limites.…”

Section: Jean-paul Vilaineunclassified

La découverte de l’ivabradine (Procoralan^®), inhibiteur sélectif du courantpacemakerI_f: Une nouvelle approche thérapeutique des cardiopathies ischémiques

Vilaine

2006

Med Sci (Paris)

View full text Add to dashboard Cite

The problem of chronic refractory angina. Report from the ESC Joint Study Group on the Treatment of Refractory Angina

Cited by 428 publications

References 126 publications

Clinical effects of enhanced external counterpulsation treatment in patients with ischemic heart failure

Clinical effects of enhanced external counterpulsation treatment in patients with ischemic heart failure

Enhanced External Counterpulsation in the Treatment of Chronic Refractory Angina: A Long‐term Follow‐up Outcome from the International Enhanced External Counterpulsation Patient Registry

La découverte de l’ivabradine (Procoralan^®), inhibiteur sélectif du courantpacemakerI_f: Une nouvelle approche thérapeutique des cardiopathies ischémiques

Contact Info

Product

Resources

About

The problem of chronic refractory angina. Report from the ESC Joint Study Group on the Treatment of Refractory Angina

Cited by 428 publications

References 126 publications

Clinical effects of enhanced external counterpulsation treatment in patients with ischemic heart failure

Clinical effects of enhanced external counterpulsation treatment in patients with ischemic heart failure

Enhanced External Counterpulsation in the Treatment of Chronic Refractory Angina: A Long‐term Follow‐up Outcome from the International Enhanced External Counterpulsation Patient Registry

La découverte de l’ivabradine (Procoralan®), inhibiteur sélectif du courantpacemakerIf: Une nouvelle approche thérapeutique des cardiopathies ischémiques

Contact Info

Product

Resources

About

La découverte de l’ivabradine (Procoralan^®), inhibiteur sélectif du courantpacemakerI_f: Une nouvelle approche thérapeutique des cardiopathies ischémiques